非诺贝特/匹伐他汀钙(Fenofibrate/Pitavastatin Calcium) - 药物靶点：HMG-CoA reductase x PPARα_在研适应症：高脂血症，高胆固醇血症_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Fenofibrate/pitavastatin、HL-PIF、Livasupril

+ [2]

靶点

HMG-CoA reductase x PPARα

作用机制

HMG-CoA reductase抑制剂(羟甲基戊二酰辅酶A合酶抑制剂)、PPARα激动剂(过氧化物酶体增长因子活化受体α激动剂)

治疗领域

内分泌与代谢疾病

在研适应症

高脂血症高胆固醇血症

非在研适应症-

原研机构

Hanlim Pharm Co., Ltd.

在研机构

Hanlim Pharm Co., Ltd.

非在研机构-

最高研发阶段批准上市

首次获批日期

韩国 (2019-04-03),

高脂血症

最高研发阶段(中国)-

特殊审评-

登录后查看首次获批时间轴

结构

分子式C20H21ClO4

InChIKeyYMTINGFKWWXKFG-UHFFFAOYSA-N

CAS号49562-28-9

查看全部结构式(2)

关联

3

项与非诺贝特/匹伐他汀钙相关的临床试验

NCT03618797 / Completed临床3期

A Multicenter, Randomized, Double-blinded, Parallel, Therapeutic Confirmatory Clinical Trial to Evaluate the Efficacy and Safety of Pitavastatin Versus Pitavastatin/Fenofibrate in Complex-dyslipidemia Patients

The purpose of this study is to evaluate the efficacy and safety of Pitavastatin versus Pitavastatin/Fenofibrate in complex-dyslipidemia patients.

开始日期2015-11-01

申办/合作机构

Hanlim Pharm Co., Ltd.

NCT02250976 / Completed临床1期

A Clinical Trial to Evaluate the Pharmacokinetics of the Fixed-dose Combination of Micronized Fenofibrate and Pitavastatin Ca Under Fed Condition in Healthy Male Volunteers

To evaluate the comparative pharmacokinetics and safety of fixed-dose combination versus coadministration of Lipilfen cap.160mg(micronized fenofibrate160mg) and Livalo tab. 2mg(pitavastatin Ca 2mg) under fed condition in healthy male volunteers.

开始日期2014-09-01

申办/合作机构

Hanlim Pharm Co., Ltd.

NCT01767610 / Completed临床1期

Open-label, Randomized, Repeated Dosing Crossover Study to Evaluate the Pharmacokinetic Interaction Between Micronized Fenofibrate and Pitavastatin in Healthy Adult Subjects

To evaluate pharmacokinetic drug interaction by comparing the steady-state pharmacokinetic characteristics of each arms after repeated administrating Lipilfen cap. 160mg and Livalo tab. 2mg through 3 period by separately or combinedly.

开始日期2013-01-01

申办/合作机构

Hanlim Pharm Co., Ltd.

100 项与非诺贝特/匹伐他汀钙相关的临床结果

登录后查看更多信息

100 项与非诺贝特/匹伐他汀钙相关的转化医学

登录后查看更多信息

100 项与非诺贝特/匹伐他汀钙相关的专利（医药）

登录后查看更多信息

122

项与非诺贝特/匹伐他汀钙相关的文献（医药）

2024-04-01·Urology

The Association of a Peritoneal Interposition Flap With Lymphocele Formation After Pelvic Lymph Node Dissection During Robotic-assisted Laparoscopic Radical Prostatectomy: A Systematic Review and Meta-analysis

Review

作者: Wagner, Joseph R ; Wagner, Andrew A ; Gershman, Boris ; Estevez, Angela ; Bansal, Utsav K ; Fleishman, Aaron ; Kaul, Sumedh ; Bain, Paul A ; Chang, Peter

OBJECTIVETo conduct a systematic review and meta-analysis to evaluate the association of a peritoneal interposition flap (PIF) with lymphocele formation following robotic-assisted laparoscopic radical prostatectomy (RALP) with pelvic lymph node dissection.METHODSWe conducted a systematic search of MEDLINE, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials through August 30, 2023, to identify randomized and nonrandomized studies comparing RALP with pelvic lymph node dissection with and without PIF. A random effects meta-analysis was then performed to evaluate the associations of PIF with 90-day postoperative outcomes.RESULTSFive randomized controlled trials (RCTs) and four observational studies, including a total of 2941 patients, were included. The use of PIF was associated with a reduced risk of 90-day symptomatic lymphocele formation after RALP when examining only RCTs (pooled odds ratios [OR] 0.44, 95% CI 0.28-0.69; I² =3%) and both RCTs and observational studies (OR 0.35, 95% CI 0.22-0.56; I² =17%). Similarly, use of PIF was associated with a reduced risk of 90-day any lymphocele formation (OR 0.40, 95% CI 0.28-0.56, I² =39%). There were no statistically significant differences in postoperative complications between the two groups (OR 0.89; 95% CI 0.69-1.14; I² =20%).CONCLUSIONUse of the PIF is associated with an approximately 50% reduced risk of symptomatic and any lymphocele formation within 90-days of surgery, and it is not associated with an increase in postoperative complications.

2023-08-01·DNA and cell biology

Aquaporin 1 Facilitates Ferroptosis, M1 Polarization, Mitochondrial Dysfunction, and Autophagy Damage on Lipopolysaccharide-Induced Macrophage Through Down-Regulation of P53 Signaling Pathway.

Article

作者: Liang, Lei ; Jia, Liao ; Liu, Dongyang ; Lv, Wuyang ; Li, Cuicui ; Jin, Yingyu

This study was designed to investigate the role of aquaporin 1 (AQP1) in ferroptosis, macrophage polarization, mitochondrial dysfunction, and impaired autophagy of lipopolysaccharide (LPS)-stimulated RAW264.7 cells and explored the underlying mechanisms. Si-AQP1-mediated AQP1 silencing RAW264.7 cells was constructed. Si-P53-mediated P53 silencing or pcDNA-P53 overexpression RAW264.7 cells was constructed. Assays of ATP, reverse transcription-quantitative polymerase chain reaction (RT-qPCR), and Mitochondrial membrane potential (JC-1) staining were performed to evaluate mitochondrial biological function. Assays of flow cytometry, reactive oxygen species (ROS) staining, western blot (WB), RT-qPCR, malondialdehyde (MDA), glutathione (GSH), and total superoxide dismutase (SOD) were performed to detect cell ferroptosis, macrophage polarization, and impaired autophagy. The involvement of the P53 pathway was revealed by WB. The results showed that LPS (30 μg/mL) could induce ferroptosis, M1 polarization, mitochondrial dysfunction, and autophagy damage in RAW264.7 cells. Meanwhile, the expression of AQP1 was increased and the expression of P53 was decreased. In addition, Pifithrin-α (PIF; 15 μM), a P53 inhibitor, significantly aggravated ferroptosis, M1 polarization, mitochondrial dysfunction, and autophagy damage as well as up-regulation of AQP1 protein expression in LPS-induced RAW264.7 cells. Interestingly, this phenomenon was markedly alleviated by Kevetrin hydrochloride (70 μM), a P53 agonist. Mechanistically, silencing AQP1 significantly alleviated ferroptosis, M1 polarization, mitochondrial dysfunction, and autophagy damage by up-regulating the expression of P53 in LPS-stimulated RAW264.7 cells. Indeed, inhibition of P53 expression by PIF treatment dramatically reversed this effect on the basis of LPS+si-AQP1. Therefore, we concluded for the first time that AQP1 can promote ferroptosis, M1 polarization, mitochondrial dysfunction, and autophagy impairment by inhibiting the expression of P53 in LPS-stimulated RAW264.7 cells, and AQP1 or P53 may be considered as a crucial determiner that can regulate the biological behavior of RAW264.7 cells stimulated by LPS.

2022-01-01·American journal of translational research3区 · 医学

Surgical treatment of the lower cervical brucellosis with osteoporosis in the northwest region of China: review of 22 cases.

3区 · 医学

Article

作者: Huang, Da-Geng ; Zhao, Qing-Peng ; Du, Jin-Peng ; Yan, Liang ; Hao, Ding-Jun ; Li, Hou-Kun ; Shan, Le-Qun ; He, Bao-Rong

OBJECTIVETo analyze the surgical treatment of patients with cervical brucellosis with osteoporosis over a 4-year period in Northwest China.METHODSFrom 2013 to 2018, 22 patients (12 males and 10 females) with lower cervical spine brucellosis (C3-C7) underwent anterior lesion debridement, decompression, bone grafting and internal fixation combined with posterior bone graft fusion and internal fixation (ADDF+PIF). The follow-up period averaged 37.4 months (ranging from 24 to 57 months).RESULTSInvolvement of 1 vertebra was observed in 3 patients, involvement of 3 vertebrae was observed in 9 patients, and involvement of 3 vertebrae was observed in 10 patients. Before surgery, 1 patient had Frankel grade B, 2 had grade C, 9 had grade D, and 10 had grade E. In the final follow-up, 12 patients had neurological deficits, 10 patients improved by one grade, 6 patients improved by two grades, and the neurological status of 6 patients remained unchanged. In all cases, it was observed that bone fusion required 6.8 months on average. The kyphosis Cobb angle was enhanced from an average of 11.5° preoperatively (range 0°-24°) to 0.13° postoperatively (range 1°-5°), and there was no vital loss of correction in the follow-up.CONCLUSIONSADDF+PIF is an effective and safe treatment for patients with lower cervical brucellosis with osteoporosis.

100 项与非诺贝特/匹伐他汀钙相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
高脂血症	韩国	Hanlim Pharm Co., Ltd.	2019-04-03

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
高胆固醇血症	临床3期	-	Hanlim Pharm Co., Ltd.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03618797 (Pubmed \| Med Lett Drugs Ther)	临床3期	血脂障碍	347	Pitavastatin/fenofibrate 2/160 mg	(窪繭遞襯選廠顧鑰餘製) = 網範壓簾壓衊選觸繭鹽醖製網齋艱鏇艱願觸鹹 (遞顧憲膚繭網憲選壓築 ) 更多	-	2020-10-01
				Pitavastatin 2 mg	(窪繭遞襯選廠顧鑰餘製) = 願蓋鬱淵鹹窪製製繭壓醖製網齋艱鏇艱願觸鹹 (遞顧憲膚繭網憲選壓築 )